作者
Hendrieke Hoftijzer, Karen A Heemstra, Hans Morreau, Marcel P Stokkel, Eleonora P Corssmit, Hans Gelderblom, Karin Weijers, Alberto M Pereira, Maya Huijberts, Ellen Kapiteijn, Johannes A Romijn, Johannes W Smit
发表日期
2009/12
期刊
European journal of endocrinology
卷号
161
期号
6
页码范围
923-931
出版商
Oxford University Press
简介
Objective
Treatment options for patients with radioactive iodine (RaI) refractory metastases of differentiated thyroid carcinoma (DTC) are limited. We studied the effects of the multitarget tyrosine kinase inhibitor sorafenib on the reinduction of RaI uptake and tumor progression.
Design
Open, single center, single arm 26-week prospective phase II study with open-ended extension.
Methods
We treated 31 patients with progressive metastatic or locally advanced RaI refractory DTC with sorafenib 400 mg b.i.d. The primary endpoint was reinduction of RaI uptake at 26 weeks. Additional endpoints were the radiological response and the influence of bone metastases.
Results
At 26 weeks of sorafenib therapy, no reinduction of RaI uptake at metastatic sites was observed, but 19 patients (59%) had a clinical beneficial response, eight of whom …
引用总数
学术搜索中的文章
H Hoftijzer, KA Heemstra, H Morreau, MP Stokkel… - European journal of endocrinology, 2009